Segment Data

9 Months Ended

Sep. 29, 2017

Segment Reporting [Abstract]

Segment Data

18. Segment Data

The two reportable segments are further described below:

• Specialty Brands includes branded medicines; and

• Specialty Generics includes specialty generic drugs, API and external manufacturing.

Selected information by reportable segment was as follows:

	Three Months Ended						Nine Months Ended
	September 29, 2017			September 30, 2016			September 29, 2017			September 30, 2016
Net sales:
Specialty Brands	$	591.4		$	633.1		$	1,743.1		$	1,757.4
Specialty Generics	189.1			239.8			643.7			767.6
Net sales of reportable segments	780.5			872.9			2,386.8			2,525.0
Other (1)	13.4			14.3			42.5			44.6
Net sales	$	793.9		$	887.2		$	2,429.3		$	2,569.6
Operating income:
Specialty Brands	$	316.6		$	334.1		$	865.7		$	897.1
Specialty Generics	40.4			63.9			179.9			260.9
Segment operating income	357.0			398.0			1,045.6			1,158.0
Unallocated amounts:
Corporate and unallocated expenses (2)	(47.6		)	(65.7		)	(163.9		)	(125.2		)
Intangible asset amortization	(173.2		)	(175.9		)	(523.0		)	(526.7		)
Restructuring and related charges, net (3)	(15.5		)	(8.7		)	(35.7		)	(34.0		)
Non-restructuring impairment charges	—			—			—			(16.9		)
Operating income	$	120.7		$	147.7		$	323.0		$	455.2

(1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.

(2) Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(3) Includes restructuring-related accelerated depreciation.

Net sales by product family within the Company's reportable segments are as follows:

	Three Months Ended				Nine Months Ended
	September 29, 2017		September 30, 2016		September 29, 2017		September 30, 2016
Acthar	$	308.7	$	327.0	$	899.9	$	873.7
Inomax	125.7		126.9		379.6		363.5
Ofirmev	75.4		75.6		224.5		217.4
Therakos immunotherapy	55.3		54.5		157.7		157.2
Hemostasis products	16.2		17.2		42.8		42.5
Other	10.1		31.9		38.6		103.1
Specialty Brands	591.4		633.1		1,743.1		1,757.4
Hydrocodone (API) and hydrocodone-containing tablets	10.0		30.8		63.3		109.8
Oxycodone (API) and oxycodone-containing tablets	13.4		28.8		60.6		97.3
Methylphenidate ER	14.3		23.4		58.2		72.3
Other controlled substances	103.9		111.8		319.0		358.4
Other products	47.5		45.0		142.6		129.8
Specialty Generics	189.1		239.8		643.7		767.6
Other (1)	13.4		14.3		42.5		44.6
Net sales	$	793.9	$	887.2	$	2,429.3	$	2,569.6

(1) Represents net sales under an ongoing supply agreement with the acquirer of the CMDS business.